Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial

Elise Mok, Guy Letellier, Jean-Marie Cuisset, André Denjean, Frédéric Gottrand, Corinne Alberti, Régis Hankard, Elise Mok, Guy Letellier, Jean-Marie Cuisset, André Denjean, Frédéric Gottrand, Corinne Alberti, Régis Hankard

Abstract

Background: Oral glutamine decreases whole body protein breakdown in Duchenne muscular dystrophy (DMD). We evaluated the functional benefit of 4 months oral glutamine in DMD.

Methodology/principal findings: 30 ambulant DMD boys were included in this double-blind, randomized crossover trial with 2 intervention periods: glutamine (0.5 g/kg/d) and placebo, 4 months each, separated by a 1-month wash-out, at 3 outpatient clinical investigation centers in France. Functional benefit was tested by comparing glutamine versus placebo on change in walking speed at 4 months. Secondary outcome measures were: 2-minute walk test, work, power, muscle mass (urinary creatinine), markers of myofibrillar protein breakdown (urinary 3-methyl-histidine/creatinine), serum creatine phospho-kinase, body composition (fat free mass, fat mass percentage), safety and oral nutrient intake. There was no improvement in the primary end point (walking speed) or in secondary measures of muscle function (2-minute walk test, work, power) in the glutamine group compared with placebo. However, subjects receiving glutamine or placebo showed no deterioration in functional measures over the course of the 9-month trial. No differences in muscle mass, markers of protein breakdown or serum creatine phosho-kinase were observed, except for a blunted increase in fat free mass in the glutamine group which led to a greater increase in fat mass percentage. Glutamine was safe and well-tolerated.

Conclusions: This trial did not identify additional benefit of 4 months oral glutamine over placebo on muscle mass or function in ambulatory DMD boys. Although apparently safe, current data cannot support routine supplementation in this population as a whole, until further research proves otherwise.

Trial registration: (ClinicalTrials.gov) NCT00296621.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Flow of participants.
Figure 1. Flow of participants.
Each 4 month intervention phase was separated by a washout period of at least 1 month.

References

    1. Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med. 1988;318:1363–1368.
    1. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989;320:1592–1597.
    1. Payne ET, Yasuda N, Bourgeois JM, Devries MC, Rodriguez MC, et al. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve. 2006;33:66–77.
    1. Archer JD, Vargas CC, Anderson JE. Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. Faseb J 2006
    1. Barton ER, Morris L, Kawana M, Bish LT, Toursel T. Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve 2005
    1. Buetler TM, Renard M, Offord EA, Schneider H, Ruegg UT. Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. Am J Clin Nutr. 2002;75:749–753.
    1. Chazalette D, Hnia K, Rivier F, Hugon G, Mornet D. alpha7B integrin changes in mdx mouse muscles after L-arginine administration. FEBS Lett. 2005;579:1079–1084.
    1. Dorchies OM, Wagner S, Vuadens O, Waldhauser K, Buetler TM, et al. Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. Am J Physiol Cell Physiol. 2006;290:C616–C625.
    1. Granchelli JA, Pollina C, Hudecki MS. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord. 2000;10:235–239.
    1. Hubner C, Lehr HA, Bodlaj R, Finckh B, Oexle K, et al. Wheat kernel ingestion protects from progression of muscle weakness in mdx mice, an animal model of Duchenne muscular dystrophy. Pediatr Res. 1996;40:444–449.
    1. Mok E, Constantin B, Favreau F, Neveux N, Magaud C, et al. l-Glutamine administration reduces oxidized glutathione and MAP kinase signaling in dystrophic muscle of mdx mice. Pediatr Res. 2008;63:268–273.
    1. Passaquin AC, Renard M, Kay L, Challet C, Mokhtarian A, et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord. 2002;12:174–182.
    1. Voisin V, Sebrie C, Matecki S, Yu H, Gillet B, et al. L-arginine improves dystrophic phenotype in mdx mice. Neurobiol Dis. 2005;20:123–130.
    1. Yoshida M, Yonetani A, Shirasaki T, Wada K. Dietary NaCl supplementation prevents muscle necrosis in a mouse model of Duchenne muscular dystrophy. Am J Physiol Regul Integr Comp Physiol. 2006;290:R449–455.
    1. Zdanowicz MM, Slonim AE, Bilaniuk I, O'Connor MM, Moyse J, et al. High protein diet has beneficial effects in murine muscular dystrophy. J Nutr. 1995;125:1150–1158.
    1. Tarnopolsky MA, Mahoney DJ, Vajsar J, Rodriguez C, Doherty TJ, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology. 2004;62:1771–1777.
    1. Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol. 2005;58:151–155.
    1. Mendell JR, Griggs RC, Moxley RT, 3rd, Fenichel GM, Brooke MH, et al. Clinical investigation in Duchenne muscular dystrophy: IV. Double-blind controlled trial of leucine. Muscle Nerve. 1984;7:535–541.
    1. Mok E, Eleouet-Da Violante C, Daubrosse C, Gottrand F, Rigal O, et al. Oral glutamine and amino acid supplementation inhibit whole-body protein degradation in children with Duchenne muscular dystrophy. Am J Clin Nutr. 2006;83:823–828.
    1. Bergstrom J, Furst P, Noree LO, Vinnars E. Intracellular free amino acid concentration in human muscle tissue. J Appl Physiol. 1974;36:693–697.
    1. Novak F, Heyland DK, Avenell A, Drover JW, Su X. Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med. 2002;30:2022–2029.
    1. Hankard R, Mauras N, Hammond D, Haymond M, Darmaun D. Is glutamine a ‘conditionally essential’ amino acid in Duchenne muscular dystrophy? Clin Nutr. 1999;18:365–369.
    1. Rennie MJ, MacLennan PA, Hundal HS, Weryk B, Smith K, et al. Skeletal muscle glutamine transport, intramuscular glutamine concentration, and muscle-protein turnover. Metabolism. 1989;38:47–51.
    1. Hankard RG, Hammond D, Haymond MW, Darmaun D. Oral glutamine slows down whole body protein breakdown in Duchenne muscular dystrophy. Pediatr Res. 1998;43:222–226.
    1. Hankard RG, Haymond MW, Darmaun D. Effect of glutamine on leucine metabolism in humans. Am J Physiol. 1996;271:E748–E754.
    1. Hankard RG, Darmaun D, Sager BK, D'Amore D, Parsons WR, et al. Response of glutamine metabolism to exogenous glutamine in humans. Am J Physiol. 1995;269:E663–670.
    1. Rossier P, Wade DT. Validity and reliability comparison of 4 mobility measures in patients presenting with neurologic impairment. Arch Phys Med Rehabil. 2001;82:9–13.
    1. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed) 1982;284:1607–1608.
    1. Elia M, Carter A, Bacon S, Winearls CG, Smith R. Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown. Br Med J (Clin Res Ed) 1981;282:351–354.
    1. Heymsfield SB, Arteaga C, McManus C, Smith J, Moffitt S. Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr. 1983;37:478–494.
    1. Bowen TR, Miller F, Mackenzie W. Comparison of oxygen consumption measurements in children with cerebral palsy to children with muscular dystrophy. J Pediatr Orthop. 1999;19:133–136.
    1. Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, et al. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve. 2007;35:36–42.
    1. Beenakker EA, Maurits NM, Fock JM, Brouwer OF, van der Hoeven JH. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Eur J Paediatr Neurol. 2005;9:387–393.
    1. Upton CJ, Tyrrell JC, Hiller EJ. Two minute walking distance in cystic fibrosis. Arch Dis Child. 1988;63:1444–1448.
    1. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the “power” of therapeutic trials based on the natural history. Muscle Nerve. 1983;6:91–103.
    1. Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008;5:e166.
    1. Griggs RC, Forbes G, Moxley RT, Herr BE. The assessment of muscle mass in progressive neuromuscular disease. Neurology. 1983;33:158–165.
    1. Blahd WH, Lederer M, Cassen B. The significance of decreased body potassium concentrations in patients with muscular dystrophy and nondystrophic relatives. N Engl J Med. 1967;276:1349–1352.
    1. Edmonds CJ, Smith T, Griffiths RD, Mackenzie J, Edwards RH. Total body potassium and water, and exchangeable sodium, in muscular dystrophy. Clin Sci (Lond) 1985;68:379–385.
    1. Hankard R, Gottrand F, Turck D, Carpentier A, Romon M, et al. Resting energy expenditure and energy substrate utilization in children with Duchenne muscular dystrophy. Pediatr Res. 1996;40:29–33.
    1. Mok E, Beghin L, Gachon P, Daubrosse C, Fontan JE, et al. Estimating body composition in children with Duchenne muscular dystrophy: comparison of bioelectrical impedance analysis and skinfold-thickness measurement. Am J Clin Nutr. 2006;83:65–69.
    1. Griggs RC, Rennie MJ. Muscle wasting in muscular dystrophy: decreased protein synthesis or increased degradation? Ann Neurol. 1983;13:125–132.
    1. Hickson RC, Czerwinski SM, Wegrzyn LE. Glutamine prevents downregulation of myosin heavy chain synthesis and muscle atrophy from glucocorticoids. Am J Physiol. 1995;268:E730–734.
    1. Salehian B, Mahabadi V, Bilas J, Taylor WE, Ma K. The effect of glutamine on prevention of glucocorticoid-induced skeletal muscle atrophy is associated with myostatin suppression. Metabolism. 2006;55:1239–1247.
    1. Hankard R, Goulet O, Ricour C, Rongier M, Colomb V, et al. Glutamine metabolism in children with short-bowel syndrome: a stable isotope study. Pediatr Res. 1994;36:202–206.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe